Bacteria and Intestinal Translocation in Surgery (Bandit)
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jun 11, 2018
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
The Bandit clinical trial is studying how bacteria might cause infections after abdominal surgery. Researchers want to learn more about the types of bacteria present in the body before and after surgery, especially in patients who develop infections at the surgical site. To do this, they will collect various samples from participants, including swabs from the skin and rectum, as well as blood and tissue samples. The main goal is to compare the bacteria found in patients with infections to those without infections, helping to understand the risk factors for surgical site infections.
To be eligible for the trial, participants must be adults over 18 years of age who are scheduled for elective abdominal surgery, regardless of gender or background. They need to understand the study language, which is German, and provide informed consent. However, pregnant or breastfeeding women, those with certain known bacterial infections, or individuals with liver disease will not be able to participate. If you decide to join the study, you can expect to provide samples before, during, and after your surgery, and you will be monitored for any signs of infection afterward. This study aims to improve our understanding of surgical site infections and potentially enhance patient care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent
- • All Ages
- • All Gender
- • Elective Abdominal Surgery
- • Age \> 18
- • All approached (laparoscopic, open)
- • All ethnic and sociodemographic backgrounds
- • Sufficient knowledge of the study language (German)
- Exclusion Criteria:
- • pregnant or lactating women
- • no operation performed (i.e. only planned)
- • insufficient knowledge of project language (German)
- • lack of informed consent
- • known colonization with multi-resistant bacteria (e.g. Methicillin-resistant Staphylococcus aureus (MRSA) or extended spectrum betalactamase (ESBL))
- • known cirrhotic liver disease
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, Switzerland
Patients applied
Trial Officials
Guido Beldi, MD, Prof
Study Director
Inselspital, University Hospital of Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials